Analyst Expectations For Myriad Genetics's Future
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Myriad Genetics (NASDAQ:MYGN) with recent ratings showing a shift towards more positive sentiment. The average 12-month price target has increased to $30.00, with a high of $35.00 and a low of $20.00. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Myriad Genetics has shown solid revenue growth but lags behind industry peers, with a high debt-to-equity ratio indicating financial risk.
September 19, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have mixed views on Myriad Genetics with a recent shift towards more positive sentiment. The average 12-month price target has increased to $30.00, indicating potential upside. However, the company's high debt-to-equity ratio poses financial risk.
The recent analyst ratings show a shift towards more positive sentiment, with an increase in the average price target to $30.00. This suggests potential upside for the stock. However, the company's high debt-to-equity ratio indicates financial risk, which could impact investor sentiment negatively. Overall, the positive shift in analyst sentiment and increased price targets suggest a likely short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100